Resolvyx Pharmaceuticals
Resolvyx Pharmaceuticals develops therapeutics with small molecule lipid mediators for the treatment of inflammatory diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | $2.5m Valuation: $125m | Late VC | |
| Total Funding | 000k | ||
Related Content
Resolvyx Pharmaceuticals focuses on developing innovative therapies that target inflammation and immune responses to treat chronic diseases. The company operates in the biopharmaceutical sector, aiming to address unmet medical needs in conditions such as asthma, cardiovascular diseases, and neurodegenerative disorders. Resolvyx's business model revolves around research and development, leveraging proprietary technology to create novel drug candidates. Revenue is generated through partnerships, licensing agreements, and potential future product sales. The primary clients include healthcare providers, pharmaceutical companies, and research institutions. The market is highly competitive, with a strong emphasis on scientific innovation and regulatory compliance.
Keywords: biopharmaceutical, inflammation, immune response, chronic diseases, asthma, cardiovascular, neurodegenerative, research, development, innovation.